LSALT peptide
Based on 1 Customer Validation
LSALT peptide is a selective DPEP-1 inhibitor with selectivity over DPEP2/3. LSALT peptide inhibits neutrophil and monocyte/macrophage recruitment, inflammation, and tissue injury. LSALT peptide reduces kidney damage, improves survival in murine sepsis and endotoxemia models. LSALT peptide can be used for the research of COVID-19, sepsis, acute respiratory distress syndrome, and acute kidney injury.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.30%
- CAS 番号: 2567713-50-0
- 分子式: C85H136N20O21
- 分子量:1774.11
-
保管条件:
Sealed storage, away from moisture and light.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
製品説明
体外実験
LSALT peptide binds specifically to human DPEP1, with no detectable binding to the closely related DPEP2 or DPEP3 proteins expressed on COS1 cells[2].
LSALT peptide (4 h) inhibits human neutrophil binding to pro-inflammatory stimulus-activated primary human lung endothelial cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
体内実験
LSALT peptide (i.v.; single dose (5 minutes post-LPS) or two doses (5 minutes and 18 hours post-LPS)) significantly improves survival in a lethal murine endotoxemia model, and reduces LPS-induced acute lung injury[2].
LSALT peptide significantly reduces mortality and organ damage in a murine polymicrobial sepsis model[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 2567713-50-0
-
性状 Solid
-
分子量 1774.11
-
分子式 C85H136N20O21
-
Color White to off-white
-
SMILES
O=C(N[C@@H](CO)C(N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@@H]([C@H](O)C)C(N1[C@@H](CCC1)C(N[C@@H](CO)C(N2[C@@H](CCC2)C(N[C@@H](CO)C(N[C@@H](CC3=CNC4=CC=CC=C34)C(N[C@@H](CC(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CC5=CC=C(C=C5)O)C(N[C@@H](CCCCN)C(N[C@@H](C)C(N[C@@H](CC(C)C)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC(C)C)N
-
配列
Leu-Ser-Ala-Leu-Thr-Pro-Ser-Pro-Ser-Trp-Leu-Lys-Tyr-Lys-Ala-Leu-NH2
-
シーケンスの短縮
LSALTPSPSWLKYKAL-NH2
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Sealed storage, away from moisture and light
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
純度とドキュメンテーション
-
データシート (262 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Somayaji R, et al. Multicentre, randomised, double-blind, placebo-controlled, proof of concept study of LSALT peptide as prevention of acute respiratory distress syndrome and acute kidney injury in patients infected with SARS-CoV-2 (COVID-19). BMJ Open. 2024;14(3):e076142. Published 2024 Mar 15. [Content Brief]
[2]. Choudhury SR, et al. Dipeptidase-1 Is an Adhesion Receptor for Neutrophil Recruitment in Lungs and Liver. Cell. 2019;178(5):1205-1221.e17. [Content Brief]
[3]. Hilpert K. Peptides in COVID-19 Clinical Trials—A Snapshot. Biologics. 2021; 1(3):300-311.
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
LSALT peptide 関連分類
HY-P11879 関連分類
Powered by Bioz